QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 A dynamic fluorescence probed glycolysis suppression process in HeLa cells treated with trichostatin A 期刊论文 ANALYST, 2022 作者:  Zhang, Fengqiu;  Shao, Changsheng;  Wu, Yahui;  Zhao, Wei;  Jing, Xumiao 收藏  |  浏览/下载：13/0  |  提交时间：2022/12/22 Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer 期刊论文 EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 卷号: 51, 页码: 15 作者:  Xiong, Kai;  Zhang, Hejun;  Du, Yang;  Tian, Jie;  Ding, Shigang 收藏  |  浏览/下载：51/0  |  提交时间：2019/12/16 The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction 期刊论文 2018, 卷号: 14, 期号: 13, 页码: 1845-1858 作者:  He, Bin;  Dai, Longfei;  Zhang, Xiaoqian;  Chen, Diyu;  Wu, Jingbang 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 Histone deacetylases (HDACs)  Histone deacetylases inhibitors (HDACis)  Hepatocellular Carcinoma cells (HCC cells)  quisinostat (JNJ-26481585)  sorafenib  synergistic effect   Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors 期刊论文 BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 卷号: 23, 期号: 19, 页码: 6258-6270 作者:  Li, Xiaoyang;  Wu, Jingde;  Li, Xiaoguang;  Mu, Weiwei;  Liu, Xueliang 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/17 HDACs  HDACIs  HDAC inhibitory activity  Antiproliferative activity  Class I and class IIa cellular activity   以组蛋白去乙酰化酶为靶标的抗癌药物研发进展 期刊论文 2010, 2010 谢爱华; 廖晨钟; 李伯玉; 山松; 邓沱; 李志斌; 宁志强; 胡伟明; 石乐明; 周家驹; 鲁先平; XIE Ai-hua; LIAO Chen-zhong; LI Bo-yu; SHAN Song; DENG Tuo; LI Zhi-bin; NING Zhi-qiang; HU Wei-ming; SHI Le-ming; ZHOU Jia-ju; LU Xian-ping 收藏  |  浏览/下载：4/0